Transgene SA (TNG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Transgene SA (TNG) has a cash flow conversion efficiency ratio of -0.152x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-18.55 Million ≈ $-21.69 Million USD) by net assets (€121.73 Million ≈ $142.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Transgene SA (TNG) net asset quality to measure how much of total assets are equity-financed.
Transgene SA - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Transgene SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TNG cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Transgene SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Transgene SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Investcorp Europe Acquisition I Corp
NASDAQ:IVCB
|
0.151x |
|
Alta Equipment Group Inc
NYSE:ALTG
|
-0.735x |
|
AVY Precision Technology
TWO:5392
|
0.037x |
|
Solvar Ltd
AU:SVR
|
0.099x |
|
WildBrain Ltd
TO:WILD
|
0.095x |
|
BEXIMCO PHARMA.GDR REGS 1
F:R2WA
|
N/A |
|
Red Hill Minerals Ltd
AU:RHI
|
0.084x |
|
Brogent Technologies
TWO:5263
|
0.031x |
Annual Cash Flow Conversion Efficiency for Transgene SA (1997–2025)
The table below shows the annual cash flow conversion efficiency of Transgene SA from 1997 to 2025. For the full company profile with market capitalisation and key ratios, see Transgene SA (TNG) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €121.73 Million ≈ $142.32 Million |
€-36.74 Million ≈ $-42.95 Million |
-0.302x | +80.52% |
| 2024-12-31 | €15.20 Million ≈ $17.78 Million |
€-23.55 Million ≈ $-27.53 Million |
-1.549x | +30.26% |
| 2023-12-31 | €15.61 Million ≈ $18.25 Million |
€-34.67 Million ≈ $-40.53 Million |
-2.221x | -313.91% |
| 2022-12-31 | €37.84 Million ≈ $44.24 Million |
€-20.30 Million ≈ $-23.74 Million |
-0.537x | -12.89% |
| 2021-12-31 | €67.21 Million ≈ $78.57 Million |
€-31.94 Million ≈ $-37.34 Million |
-0.475x | +16.91% |
| 2020-12-31 | €50.25 Million ≈ $58.75 Million |
€-28.74 Million ≈ $-33.60 Million |
-0.572x | -67.66% |
| 2019-12-31 | €65.70 Million ≈ $76.81 Million |
€-22.41 Million ≈ $-26.20 Million |
-0.341x | +55.88% |
| 2018-12-31 | €36.70 Million ≈ $42.91 Million |
€-28.38 Million ≈ $-33.18 Million |
-0.773x | +38.59% |
| 2017-12-31 | €28.09 Million ≈ $32.84 Million |
€-35.37 Million ≈ $-41.35 Million |
-1.259x | -74.35% |
| 2016-12-31 | €46.50 Million ≈ $54.37 Million |
€-33.59 Million ≈ $-39.26 Million |
-0.722x | +57.54% |
| 2015-12-31 | €26.55 Million ≈ $31.04 Million |
€-45.15 Million ≈ $-52.79 Million |
-1.701x | -125.29% |
| 2014-12-31 | €71.84 Million ≈ $83.99 Million |
€-54.24 Million ≈ $-63.41 Million |
-0.755x | +14.82% |
| 2013-12-31 | €56.62 Million ≈ $66.20 Million |
€-50.19 Million ≈ $-58.67 Million |
-0.886x | -72.06% |
| 2012-12-31 | €99.58 Million ≈ $116.42 Million |
€-51.29 Million ≈ $-59.97 Million |
-0.515x | -64.95% |
| 2011-12-31 | €141.42 Million ≈ $165.33 Million |
€-44.16 Million ≈ $-51.63 Million |
-0.312x | -130.02% |
| 2010-12-31 | €183.62 Million ≈ $214.67 Million |
€-24.93 Million ≈ $-29.14 Million |
-0.136x | +50.28% |
| 2009-12-31 | €68.56 Million ≈ $80.16 Million |
€-18.72 Million ≈ $-21.89 Million |
-0.273x | -10.00% |
| 2008-12-31 | €94.22 Million ≈ $110.16 Million |
€-23.39 Million ≈ $-27.34 Million |
-0.248x | -1228.28% |
| 2007-12-31 | €110.94 Million ≈ $129.70 Million |
€-2.07 Million ≈ $-2.42 Million |
-0.019x | +98.18% |
| 2006-12-31 | €18.98 Million ≈ $22.19 Million |
€-19.54 Million ≈ $-22.84 Million |
-1.029x | +23.32% |
| 2004-12-31 | €14.23 Million ≈ $16.64 Million |
€-19.11 Million ≈ $-22.34 Million |
-1.343x | -154.45% |
| 2003-12-31 | €34.52 Million ≈ $40.36 Million |
€-18.21 Million ≈ $-21.29 Million |
-0.528x | -81.78% |
| 2002-12-31 | €55.21 Million ≈ $64.54 Million |
€-16.02 Million ≈ $-18.73 Million |
-0.290x | -35.93% |
| 2001-12-31 | €73.63 Million ≈ $86.08 Million |
€-15.72 Million ≈ $-18.38 Million |
-0.214x | +66.64% |
| 2000-12-31 | €34.79 Million ≈ $40.67 Million |
€-22.27 Million ≈ $-26.03 Million |
-0.640x | -155.78% |
| 1999-12-31 | €55.48 Million ≈ $64.86 Million |
€-13.88 Million ≈ $-16.23 Million |
-0.250x | +45.04% |
| 1998-12-31 | €73.49 Million ≈ $85.92 Million |
€-33.47 Million ≈ $-39.13 Million |
-0.455x | +19.95% |
| 1997-12-31 | €20.68 Million ≈ $24.18 Million |
€-11.77 Million ≈ $-13.76 Million |
-0.569x | -- |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) posi… Read more